{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T22:08:16Z","timestamp":1648764496906},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,6,27]],"date-time":"2007-06-27T00:00:00Z","timestamp":1182902400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1007\/s11899-007-0023-1","type":"journal-article","created":{"date-parts":[[2007,6,26]],"date-time":"2007-06-26T04:42:55Z","timestamp":1182832975000},"page":"169-175","source":"Crossref","is-referenced-by-count":1,"title":["Modern treatment programs for adults with acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"2","author":[{"given":"Farhad","family":"Ravandi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,6,27]]},"reference":[{"key":"23_CR1","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/cncr.11664","volume":"98","author":"S. Faderl","year":"2003","unstructured":"Faderl S, Jeha S, Kantarjian HM: The biology and therapy of adult acute lymphoblastic leukemia. Cancer 2003, 98:1337\u20131354.","journal-title":"Cancer"},{"key":"23_CR2","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1053\/beha.2002.0224","volume":"15","author":"P. Kebriaei","year":"2002","unstructured":"Kebriaei P, Anastasi J, Larson RA: Acute lymphoblastic leukaemia: diagnosis and classification. Best Pract Res Clin Haematol 2002, 15:597\u2013621.","journal-title":"Best Pract Res Clin Haematol"},{"key":"23_CR3","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","volume":"354","author":"C.H. Pui","year":"2006","unstructured":"Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 2006, 354:166\u2013178.","journal-title":"N Engl J Med"},{"key":"23_CR4","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.2003.02.053","volume":"21","author":"N. Boissel","year":"2003","unstructured":"Boissel N, Auclerc MF, Lheritier V, et al.: Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003, 21:774\u2013780.","journal-title":"J Clin Oncol"},{"key":"23_CR5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2141.1994.tb04982.x","volume":"88","author":"H.M. Kantarjian","year":"1994","unstructured":"Kantarjian HM, O\u2019Brien S, Smith T, et al.: Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen. Br J Haematol 1994, 88:94\u2013100.","journal-title":"Br J Haematol"},{"key":"23_CR6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/mpo.2950190411","volume":"19","author":"B. Jones","year":"1991","unstructured":"Jones B, Freeman AI, Shuster JJ, et al.: Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 1991, 19:269\u2013275.","journal-title":"Med Pediatr Oncol"},{"key":"23_CR7","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2002-08-2454","volume":"101","author":"B.C. Bostrom","year":"2003","unstructured":"Bostrom BC, Sensel MR, Sather HN, et al.: Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children\u2019s Cancer Group. Blood 2003, 101:3809\u20133817.","journal-title":"Blood"},{"key":"23_CR8","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2141.2005.05509.x","volume":"129","author":"C.D. Mitchell","year":"2005","unstructured":"Mitchell CD, Richards SM, Kinsey SE, et al.: Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005, 129:734\u2013745.","journal-title":"Br J Haematol"},{"key":"23_CR9","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/(SICI)1097-0142(20000415)88:8<1964::AID-CNCR27>3.0.CO;2-1","volume":"88","author":"C.A. Hurwitz","year":"2000","unstructured":"Hurwitz CA, Silverman LB, Schorin MA, et al.: Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 2000, 88:1964\u20131969.","journal-title":"Cancer"},{"key":"23_CR10","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","volume":"101","author":"H. Kantarjian","year":"2004","unstructured":"Kantarjian H, Thomas D, O\u2019Brien S, et al.: Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004, 101:2788\u20132801.","journal-title":"Cancer"},{"key":"23_CR11","first-page":"1556","volume":"92","author":"R.A. Larson","year":"1998","unstructured":"Larson RA, Dodge RK, Linker CA, et al.: A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998, 92:1556\u20131564.","journal-title":"Blood"},{"key":"23_CR12","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V99.3.863","volume":"99","author":"L. Annino","year":"2002","unstructured":"Annino L, Vegna ML, Camera A, et al.: Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002, 99:863\u2013871.","journal-title":"Blood"},{"key":"23_CR13","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","volume":"106","author":"J.M. Rowe","year":"2005","unstructured":"Rowe JM, Buck G, Burnett AK, et al.: Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993. Blood 2005, 106:3760\u20133767.","journal-title":"Blood"},{"key":"23_CR14","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0889-8588(05)70188-X","volume":"14","author":"N. Gokbuget","year":"2000","unstructured":"Gokbuget N, Hoelzer D, Arnold R, et al.: Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am 2000, 14:1307\u20131325, ix.","journal-title":"Hematol Oncol Clin North Am"},{"key":"23_CR15","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1200\/JCO.2004.10.050","volume":"22","author":"X. Thomas","year":"2004","unstructured":"Thomas X, Boiron JM, Huguet F, et al.: Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004, 22:4075\u20134086.","journal-title":"J Clin Oncol"},{"key":"23_CR16","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1200\/JCO.1996.14.9.2480","volume":"14","author":"M. Weiss","year":"1996","unstructured":"Weiss M, Maslak P, Feldman E, et al.: Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J Clin Oncol 1996, 14:2480\u20132485.","journal-title":"J Clin Oncol"},{"key":"23_CR17","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/sj.leu.2404152","volume":"20","author":"F. Ravandi","year":"2006","unstructured":"Ravandi F: Role of cytokines in the treatment of acute leukemias: a review. Leukemia 2006, 20:563\u2013571.","journal-title":"Leukemia"},{"key":"23_CR18","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","volume":"85","author":"R.A. Larson","year":"1995","unstructured":"Larson RA, Dodge RK, Burns CP, et al.: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood 1995, 85:2025\u20132037.","journal-title":"Blood"},{"key":"23_CR19","first-page":"222","volume":"83","author":"J.M. Ribera","year":"1998","unstructured":"Ribera JM, Ortega JJ, Oriol A, et al.: Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology. Haematologica 1998, 83:222\u2013230.","journal-title":"Haematologica"},{"key":"23_CR20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1365-2141.1997.3613175.x","volume":"99","author":"I.J. Durrant","year":"1997","unstructured":"Durrant IJ, Prentice HG, Richards SM: Intensification of treatment for adults with acute lymphoblastic leukaemia: results of U.K. Medical Research Council randomized trial UKALL XA. Medical Research Council Working Party on Leukaemia in Adults. Br J Haematol 1997, 99:84\u201392.","journal-title":"Br J Haematol"},{"issue":"Suppl2","key":"23_CR21","first-page":"178","volume":"6","author":"P.A. Cassileth","year":"1992","unstructured":"Cassileth PA, Andersen JW, Bennett JM, et al.: Adult acute lymphocytic leukemia: the Eastern Cooperative Oncology Group experience. Leukemia 1992, 6(Suppl 2):178\u2013181.","journal-title":"Leukemia"},{"key":"23_CR22","first-page":"425","volume":"5","author":"J. Cuttner","year":"1991","unstructured":"Cuttner J, Mick R, Budman DR, et al.: Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB study. Leukemia 1991, 5:425\u2013431.","journal-title":"Leukemia"},{"key":"23_CR23","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1365-2141.1996.00394.x","volume":"92","author":"F. Mandelli","year":"1996","unstructured":"Mandelli F, Annino L, Rotoli B: The GIMEMA ALL 0183 trial: analysis of 10-year follow-up. GIMEMA Cooperative Group, Italy. Br J Haematol 1996, 92:665\u2013672.","journal-title":"Br J Haematol"},{"key":"23_CR24","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2005-11-4666","volume":"108","author":"H.M. Lazarus","year":"2006","unstructured":"Lazarus HM, Richards SM, Chopra R, et al.: Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII\/ECOG E2993. Blood 2006, 108:465\u2013472.","journal-title":"Blood"},{"key":"23_CR25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.V55.2.199.199","volume":"55","author":"G.A. Omura","year":"1980","unstructured":"Omura GA, Moffitt S, Vogler WR, Salter MM: Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis. Blood 1980, 55:199\u2013204.","journal-title":"Blood"},{"key":"23_CR26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood.V71.1.123.123","volume":"71","author":"D. Hoelzer","year":"1988","unstructured":"Hoelzer D, Thiel E, Loffler H, et al.: Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988, 71:123\u2013131.","journal-title":"Blood"},{"key":"23_CR27","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1182\/blood.V86.6.2091.bloodjournal8662091","volume":"86","author":"J. Cortes","year":"1995","unstructured":"Cortes J, O\u2019Brien SM, Pierce S, et al.: The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 1995, 86:2091\u20132097.","journal-title":"Blood"},{"key":"23_CR28","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/blood.V72.5.1784.1784","volume":"72","author":"H.M. Kantarjian","year":"1988","unstructured":"Kantarjian HM, Walters RS, Smith TL, et al.: Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood 1988, 72:1784\u20131789.","journal-title":"Blood"},{"key":"23_CR29","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0889-8588(05)70190-8","volume":"14","author":"A. Thiebaut","year":"2000","unstructured":"Thiebaut A, Vernant JP, Degos L, et al.: Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am 2000, 14:1353\u20131366, x.","journal-title":"Hematol Oncol Clin North Am"},{"key":"23_CR30","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1182\/blood-2003-10-3560","volume":"104","author":"M. Hunault","year":"2004","unstructured":"Hunault M, Harousseau JL, Delain M, et al.: Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 2004, 104:3028\u20133037.","journal-title":"Blood"},{"key":"23_CR31","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.1990.8.5.820","volume":"8","author":"J.R. Wingard","year":"1990","unstructured":"Wingard JR, Piantadosi S, Santos GW, et al.: Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia. J Clin Oncol 1990, 8:820\u2013830.","journal-title":"J Clin Oncol"},{"key":"23_CR32","doi-asserted-by":"crossref","unstructured":"Rowe JM, Buck G, Fielding A, et al.: In adults with standard-risk acute lymphoblastic leukemia (ALL) the greatest benefit is achieved from an allogeneic transplant in first complete remission (CR) and an autologous transplant is less effective than conventional consolidation\/maintenance chemotherapy: final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993) [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:Abstract 2.","DOI":"10.1182\/blood.V108.11.2.2"},{"key":"23_CR33","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1046\/j.1365-2141.2000.01851.x","volume":"108","author":"M. Michallet","year":"2000","unstructured":"Michallet M, Tanguy ML, Socie G, et al.: Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de Moelle (SFGM). Br J Haematol 2000, 108:400\u2013407.","journal-title":"Br J Haematol"},{"key":"23_CR34","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1046\/j.1468-0734.2002.00066.x","volume":"6","author":"S. Faderl","year":"2002","unstructured":"Faderl S, Garcia-Manero G, Thomas DA, Kantarjian HM: Philadelphia chromosome-positive acute lymphoblastic leukemia: current concepts and future perspectives. Rev Clin Exp Hematol 2002, 6:142\u2013160.","journal-title":"Rev Clin Exp Hematol"},{"key":"23_CR35","first-page":"3983","volume":"93","author":"M. Wetzler","year":"1999","unstructured":"Wetzler M, Dodge RK, Mrozek K, et al.: Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood 1999, 93:3983\u20133993.","journal-title":"Blood"},{"key":"23_CR36","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","volume":"109","author":"A.V. Moorman","year":"2007","unstructured":"Moorman AV, Harrison CJ, Buck GA, et al.: Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII \/ Eastern Cooperative Oncology Group (ECOG) 2993 Trial. Blood 2007, 109:3189\u20133197.","journal-title":"Blood"},{"key":"23_CR37","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"B.J. Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561\u2013566.","journal-title":"Nat Med"},{"key":"23_CR38","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"C.L. Sawyers","year":"2002","unstructured":"Sawyers CL, Hochhaus A, Feldman E, et al.: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99:3530\u20133539.","journal-title":"Blood"},{"key":"23_CR39","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","volume":"100","author":"O.G. Ottmann","year":"2002","unstructured":"Ottmann OG, Druker BJ, Sawyers CL, et al.: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002, 100:1965\u20131971.","journal-title":"Blood"},{"key":"23_CR40","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V97.7.1999","volume":"97","author":"Y. Kano","year":"2001","unstructured":"Kano Y, Akutsu M, Tsunoda S, et al.: In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001, 97:1999\u20132007.","journal-title":"Blood"},{"key":"23_CR41","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","volume":"103","author":"D.A. Thomas","year":"2004","unstructured":"Thomas DA, Faderl S, Cortes J, et al.: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004, 103:4396\u20134407.","journal-title":"Blood"},{"key":"23_CR42","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1182\/blood-2004-04-1389","volume":"104","author":"M. Towatari","year":"2004","unstructured":"Towatari M, Yanada M, Usui N, et al.: Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 2004, 104:3507\u20133512.","journal-title":"Blood"},{"key":"23_CR43","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2006-03-011908","volume":"109","author":"A. Labarthe de","year":"2007","unstructured":"de Labarthe A, Rousselot P, Huguet-Rigal F, et al.: Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007, 109:1408\u20131413.","journal-title":"Blood"},{"key":"23_CR44","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","volume":"108","author":"B. Wassmann","year":"2006","unstructured":"Wassmann B, Pfeifer H, Goekbuget N, et al.: Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006, 108:1469\u20131477.","journal-title":"Blood"},{"key":"23_CR45","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","volume":"24","author":"M. Yanada","year":"2006","unstructured":"Yanada M, Takeuchi J, Sugiura I, et al.: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006, 24:460\u2013466.","journal-title":"J Clin Oncol"},{"key":"23_CR46","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","volume":"109","author":"M. Vignetti","year":"2007","unstructured":"Vignetti M, Fazi P, Cimino G, et al.: Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell\u2019Adulto (GIMEMA) LAL0201-B protocol. Blood 2007, 109:3676\u20133678.","journal-title":"Blood"},{"key":"23_CR47","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/sj.leu.2404320","volume":"20","author":"A. Delannoy","year":"2006","unstructured":"Delannoy A, Delabesse E, Lheritier V, et al.: Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 2006, 20:1526\u20131532.","journal-title":"Leukemia"},{"key":"23_CR48","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M. Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531\u20132541.","journal-title":"N Engl J Med"},{"key":"23_CR49","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H. Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542\u20132551.","journal-title":"N Engl J Med"},{"key":"23_CR50","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1182\/blood-2004-02-0405","volume":"104","author":"K.A. Blum","year":"2004","unstructured":"Blum KA, Lozanski G, Byrd JC: Adult Burkitt leukemia and lymphoma. Blood 2004, 104:3009\u20133020.","journal-title":"Blood"},{"key":"23_CR51","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","volume":"14","author":"I. Magrath","year":"1996","unstructured":"Magrath I, Adde M, Shad A, et al.: Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996, 14:925\u2013934.","journal-title":"J Clin Oncol"},{"key":"23_CR52","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495","volume":"87","author":"D. Hoelzer","year":"1996","unstructured":"Hoelzer D, Ludwig WD, Thiel E, et al.: Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996, 87:495\u2013508.","journal-title":"Blood"},{"key":"23_CR53","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1200\/JCO.1999.17.8.2461","volume":"17","author":"D.A. Thomas","year":"1999","unstructured":"Thomas DA, Cortes J, O\u2019Brien S, et al.: Hyper-CVAD program in Burkitt\u2019s-type adult acute lymphoblastic leukemia. J Clin Oncol 1999, 17:2461\u20132470.","journal-title":"J Clin Oncol"},{"key":"23_CR54","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/cncr.20143","volume":"100","author":"D.A. Rizzieri","year":"2004","unstructured":"Rizzieri DA, Johnson JL, Niedzwiecki D, et al.: Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer 2004, 100:1438\u20131448.","journal-title":"Cancer"},{"key":"23_CR55","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/cncr.10365","volume":"94","author":"J. Cortes","year":"2002","unstructured":"Cortes J, Thomas D, Rios A, et al.: Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma\/leukemia. Cancer 2002, 94:1492\u20131499.","journal-title":"Cancer"},{"key":"23_CR56","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","volume":"106","author":"D.A. Thomas","year":"2006","unstructured":"Thomas DA, Faderl S, O\u2019Brien S, et al.: Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006, 106:1569\u20131580.","journal-title":"Cancer"},{"key":"23_CR57","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1182\/blood-2002-01-0110","volume":"99","author":"D. Hoelzer","year":"2002","unstructured":"Hoelzer D, Gokbuget N, Digel W, et al.: Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 2002, 99:4379\u20134385.","journal-title":"Blood"},{"key":"23_CR58","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1182\/blood-2003-12-4428","volume":"104","author":"D.A. Thomas","year":"2004","unstructured":"Thomas DA, O\u2019Brien S, Cortes J, et al.: Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 2004, 104:1624\u20131630.","journal-title":"Blood"},{"key":"23_CR59","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2005-04-1754","volume":"107","author":"A. Vitale","year":"2006","unstructured":"Vitale A, Guarini A, Ariola C, et al.: Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood 2006, 107:473\u2013479.","journal-title":"Blood"},{"key":"23_CR60","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1002\/cncr.10552","volume":"94","author":"B.S. Dabaja","year":"2002","unstructured":"Dabaja BS, Ha CS, Thomas DA, et al.: The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma. Cancer 2002, 94:2738\u20132744.","journal-title":"Cancer"},{"key":"23_CR61","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1517\/13543784.15.12.1601","volume":"15","author":"F. Ravandi","year":"2006","unstructured":"Ravandi F, Gandhi V: Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma. Expert Opin Investig Drugs 2006, 15:1601\u20131613.","journal-title":"Expert Opin Investig Drugs"},{"key":"23_CR62","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood-2005-06-2553","volume":"107","author":"J. O\u2019Neil","year":"2006","unstructured":"O\u2019Neil J, Calvo J, McKenna K, et al.: Activating Notch1 mutations in mouse models of T-ALL. Blood 2006, 107:781\u2013785.","journal-title":"Blood"},{"key":"23_CR63","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/ng1425","volume":"36","author":"C. Graux","year":"2004","unstructured":"Graux C, Cools J, Melotte C, et al.: Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004, 36:1084\u20131089.","journal-title":"Nat Genet"},{"key":"23_CR64","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/S0889-8588(05)70187-8","volume":"14","author":"W. Stock","year":"2000","unstructured":"Stock W, Estrov Z: Studies of minimal residual disease in acute lymphocytic leukemia. Hematol Oncol Clin North Am 2000, 14:1289\u20131305, viii\u2013ix.","journal-title":"Hematol Oncol Clin North Am"},{"key":"23_CR65","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1182\/blood.V87.12.5251.bloodjournal87125251","volume":"87","author":"J. Brisco","year":"1996","unstructured":"Brisco J, Hughes E, Neoh SH, et al.: Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood 1996, 87:5251\u20135256.","journal-title":"Blood"},{"key":"23_CR66","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1200\/JCO.2002.20.4.1094","volume":"20","author":"F.Y. Mortuza","year":"2002","unstructured":"Mortuza FY, Papaioannou M, Moreira IM, et al.: Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 2002, 20:1094\u20131104.","journal-title":"J Clin Oncol"},{"key":"23_CR67","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","volume":"107","author":"M. Bruggemann","year":"2006","unstructured":"Bruggemann M, Raff T, Flohr T, et al.: Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006, 107:1116\u20131123.","journal-title":"Blood"},{"key":"23_CR68","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood-2006-07-037093","volume":"109","author":"T. Raff","year":"2007","unstructured":"Raff T, Gokbuget N, Luschen S, et al.: Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06\/99 and 07\/03 trials. Blood 2007, 109:910\u2013915.","journal-title":"Blood"},{"key":"23_CR69","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2002.07.116","volume":"20","author":"C. Linker","year":"2002","unstructured":"Linker C, Damon L, Ries C, Navarro W: Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 2002, 20:2464\u20132471.","journal-title":"J Clin Oncol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-007-0023-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-007-0023-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-007-0023-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T17:59:07Z","timestamp":1587664747000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-007-0023-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,27]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["23"],"URL":"https:\/\/doi.org\/10.1007\/s11899-007-0023-1","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,27]]}}}